“…Inflammation in cancer could be a target for immunomodulatory treatment, but could also represent an unfavourable factor for patients, being responsible for cancer progression. The combined peripheral neutrophil–platelet index seems to be an unfavourable predictor factor for overall survival in resectable oesophageal squamous cell carcinoma (ESCC) patients, as shown by Peng et al [ 11 ].…”